Twilio to Participate in William Blair 45th Annual Growth Stock Conference

A live webcast will be available on Twilio’s investor relations website

SAN FRANCISCO--(BUSINESS WIRE)-- Twilio (NYSE: TWLO), the customer engagement platform that drives real-time, personalized experiences for today’s leading brands, today announced that Chief Executive Officer Khozema Shipchandler will participate in a fireside chat at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025 at 6:40 a.m. (PT) / 9:40 a.m. (ET).

A live webcast and replay will be available on Twilio’s investor relations website at investors.twilio.com.

Disclosure Information

Twilio uses its investor relations website (https://investors.twilio.com) and the X (formerly “Twitter”) accounts of the company (@twilio) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Twilio Inc.

Today's leading companies trust Twilio's Customer Engagement Platform (CEP) to build direct, personalized relationships with their customers everywhere in the world. Twilio enables companies to use communications and data to add intelligence and security to every step of the customer journey, from sales to marketing to growth, customer service and many more engagement use cases in a flexible, programmatic way. Across 180 countries and territories, millions of developers and hundreds of thousands of businesses use Twilio to create magical experiences for their customers. For more information about Twilio (NYSE: TWLO) visit www.twilio.com.

Source: Twilio Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250528887278/en/

Investor Contact:
Bryan Vaniman
[email protected]
or
Media Contact:
Caitlin Epstein
[email protected]

Source: Twilio

You May Also Be Interested In

• Twilio (TWLO) PT Raised to $290 at Rosenblatt
• CenterPoint Energy Declares Regular Common Stock Dividend of $0.2400
• Octant Announces First Patient Dosed in Phase 1b/2 Clinical Study of OCT-980 for the Treatment of Retinitis Pigmentosa